Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
Life expectancy at least 3 months
Diagnosis of a solid tumor which is unresectable in which no approved effective therapy exists or for subjects who are intolerable to such therapy. The initial enrollment will focus on non-small cell lung, gastric/esophageal adenocarcinoma, soft tissue sarcoma, transitional cell carcinoma, and pancreatic cancer including ampulla of Vater tumors
Adequate tumor sample
Adequate recovery (baseline or Grade 1) from recent therapy. At least 1 week must have elapsed from the time of a minor surgery, and at least 8 weeks for major surgery or radiation therapy
You may not be if
Subjects with known brain metastasis.
Medical History and Concurrent Diseases:
History of thrombo-embolic disease within the last six months requiring therapeutic anticoagulation
Subjects with history of poor wound healing or non healing ulcers
Uncontrolled or significant cardiovascular disease
Allergies and Adverse Drug Reactions:
History of allergy to brivanib its drug class, or related compounds
Prohibited Treatments and/or Therapies:
Exposure to any investigational drug within 4 weeks of enrollment
Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiotherapy, standard or investigational. Subjects may continue to receive hormone replacement therapy
